Inhibitors Targeting SARS‐CoV‐2 Papain‐Like Protease: Screening, Design, Synthesis, and Biological Evaluation
ChemMedChem · 2026-05-14 · 21 (9)
DOI: 10.1002/cmdc.202600007 ↗At a glance
Journal article in ChemMedChem, published online on 2026-05-08. Written by Elena-Oriana Iuga and 11 co-authors. Institution: Institute of Pharmacy, Pharmaceutical/Medicinal Chemistry, Eberhard Karls University, Tübingen, Germany. Major MEDLINE topics: Drug Design, Antiviral Agents, SARS-CoV-2, Protease Inhibitors. 54 references. The full text is freely available (open access, CC BY 4.0).
Abstract (original language)
Despite the availability of vaccines and antiviral drugs, SARS‐CoV‐2 still presents a global health threat, emphasizing the need for new therapeutic targets beyond the main protease and RNA‐dependent RNA polymerase. The papain‐like protease (PL pro ) is a highly conserved and essential viral enzyme that drives polyprotein processing and suppresses host innate immune responses through its deubiquitinating and deISGylating activities. This study employed two approaches to identify new PL pro inhibitors: (i) the design and synthesis of a range of non‐covalent PL pro inhibitors based on a lead compound, GRL0617. (ii) Screening the in‐house library for new covalent PL pro inhibitors. Biochemical assays demonstrated effective inhibition of PL pro activity, particularly with the non‐covalent inhibitor 2t ( TPG‐2t , IC 50 = 0.634 µM) and with potential covalent inhibitors such as 13e (IC 50 = 22.0 µM) and 13f ( TPG‐13f , IC 50 = 5.0 µM). 2t exhibited antiviral activity (EC 50 = 2.89 µM) without causing cellular toxicity. Molecular modeling suggests that 2t can establish stable binding interactions within the PL pro active site. Therefore, inhibitor 2t could be a promising candidate for future antiviral development.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Institute of Pharmacy, Pharmaceutical/Medicinal Chemistry, Eberhard Karls University, Tübingen, Germany.
- Tübingen Center for Academic Drug Discovery (TüCAD2), Eberhard Karls University, Tübingen, Germany.
- São Carlos Institute of Physics, University of São Paulo (USP), São Carlos, Brazil.
- Faculdade de Farmácia, Universidade Federal de Minas Gerais (UFMG), Belo Horizonte, Brazil.
- Faculdade de Farmácia, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil.
- Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, California, USA.
ORCID profiles: Thanigaimalai Pillaiyar
Cite
APA
Iuga, E. O., Gone, N., de Godoy, M. O., Verissimo, G. C., de Jesus Agostinetto, G., Urich, L., Krüger, N., Kronenberger, T., Guido, R. V. C., O'Donoghue, A. J., Laufer, S. A., & Pillaiyar, T. (2026). Inhibitors Targeting SARS‐CoV‐2 Papain‐Like Protease: Screening, Design, Synthesis, and Biological Evaluation. ChemMedChem, 21(9). https://doi.org/10.1002/cmdc.202600007
Vancouver
Iuga EO, Gone N, de Godoy MO, Verissimo GC, de Jesus Agostinetto G, Urich L, et al. Inhibitors Targeting SARS‐CoV‐2 Papain‐Like Protease: Screening, Design, Synthesis, and Biological Evaluation. ChemMedChem. 2026;21(9). doi:10.1002/cmdc.202600007
BibTeX
@article{Iuga2026,
author = {Iuga, Elena-Oriana and Gone, Nilu and de Godoy, Mariana Ortiz and Verissimo, Gabriel Correa and de Jesus Agostinetto, Giovanna and Urich, Liam and Krüger, Nadine and Kronenberger, Thales and Guido, Rafael Victorio Carvalho and O'Donoghue, Anthony J and Laufer, Stefan A and Pillaiyar, Thanigaimalai},
title = {Inhibitors Targeting SARS‐CoV‐2 Papain‐Like Protease: Screening, Design, Synthesis, and Biological Evaluation},
journal = {ChemMedChem},
year = {2026},
volume = {21},
number = {9},
doi = {10.1002/cmdc.202600007}
}
EUVIMED